Patient-Reported Outcomes for Acute Graft-versus-Host Disease Prevention and Treatment Trials

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 3, 2010, Pages 295-300

  Lee, Stephanie J ^a   Williams, Loretta A ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute graft versus host disease; Clinical trials; Food and Drug Administration; Patient reported outcomes

Indexed keywords

BECLOMETASONE DIPROPIONATE; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; EXPERIMENTAL DESIGN; FOOD AND DRUG ADMINISTRATION; GRAFT SURVIVAL; HUMAN; INSTRUMENT VALIDATION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; QUALITY OF LIFE; RELIABILITY; REVIEW; SELF REPORT; SENSITIVITY AND SPECIFICITY; SHORT FORM 36; T CELL DEPLETION; VALIDATION PROCESS;

CLINICAL TRIALS AS TOPIC; GRAFT VS HOST DISEASE; HUMANS; PATIENT SATISFACTION; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 75749155357     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.08.021     Document Type: Review

References (18)

1. Rhodes V.A., and Watson P.M. Symptom distress-the concept: past and present. Semin Oncol Nurs 3 (1987) 242-247
2. Patient Reported Outcome (PRO-CTCAE). Available at: https://wiki.nci.nih.gov/display/CTMS/Patient+Reported+Outcome+(PRO-CTCAE). Accessed July 3, 2009.
3. Food and Drug Administration. Draft Guidance for Industry. PRO measures: use in medical product development to support labeling claims. 2006. Available at: http://www.fda.gov/cder/guidance. Accessed May 4, 2009.
4. Wang X.S., Shi Q., Williams L.A., et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 113 (2008) 2102-2109
5. Giralt S., Cleeland C.S., Reuben J., et al. Measuring multiple symptoms and inflammatory cytokines related to acute GVHD in AML/MDS patients undergoing allogeneic BMT [abstr 1426]. Blood 106 (2005) 412A
6. Abernethy A.P., Herndon II J.E., Wheeler J.L., et al. Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. J Pain Symptom Manage 37 (2009) 1027-1038
7. Basch E., Iasonos A., Barz A., et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25 (2007) 5374-5380
8. Berry P.H., and Dahl J.L. The new JCAHO pain standards: implications for pain management nurses. Pain Manag Nurs 1 (2000) 3-12
9. Biedrzycki B.A. Could fatigue become the sixth vital sign?. ONS News 18 1 (2003) 4-5
10. Bultz B.D., and Carlson L.E. Emotional distress: the sixth vital sign in cancer care. J Clin Oncol 23 (2005) 6440-6441
11. Ware J.E., Kosinski M., and Keller S.D. SF-36 Physical and Mental Health Summary Scales: A User's Manual. New England Medical Center (1994), The Health Institute, Boston, MA
12. Ware J.E., Snow K.K., Kosinski M., and Gandek B. SF-36 Health Survey: A Manual and Interpretation Guide. New England Medical Center (1993), The Health Institute, Boston, MA
13. McQuellon R.P., Russell G.B., Cella D.F., et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 19 (1997) 357-368
14. Cleeland C.S., Mendoza T.R., Wang X.S., et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89 (2000) 1634-1646
15. Altmaier E.M., Ewell M., McQuellon R., et al. The effect of unrelated donor marrow transplantation on health-related quality of life: a report of the unrelated donor marrow transplantation trial (T-cell depletion trial). Biol Blood Marrow Transplant 12 (2006) 648-655
16. Wagner J.E., Thompson J.S., Carter S.L., and Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre, randomised phase II-III trial. Lancet 366 (2005) 733-741
17. Lee S.J., Kim H.T., Ho V.T., et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 38 (2006) 305-310
18. Williams L.A., Giralt S.A., Wang X.S., et al. Measuring the symptom burden of allogeneic hematopoietic stem cell transplantation in patients with and without acute graft-versus-host disease [abstract 49]. Biol Blood Marrow Transplant 15 (2009) 20-21